BioLineRx Ltd. (NASDAQ:BLRX) Q3 2024 Earnings Conference Call November 25, 2024 8:30 AM ET

Company Participants

John Lacey - Head of IR & Corporate Communications
Phil Serlin - CEO
Mali Zeevi - CFO

Conference Call Participants

Joe Pantginis - HC Wainwright
Justin Walsh - Jones Trading
John Vandermosten - Zacks

Operator

Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Third Quarter 2024 Financial Results Conference Call. All participants are presently in a listen-only mode. Following management's formal presentation, instructions will be given for the question-and-answer session.

I would now like to turn over the call to John Lacey, Head of Investor Relations and Corporate Communications. John, please go ahead.

John Lacey

Thank you, operator. Welcome, everyone. Thank you for joining us on our third quarter 2024 results conference call. Earlier today, we issued a press release, a copy of which is available in the Investor Relations section of our website. It was also filed as a 6-Ks.

I'd like to remind you that certain statements we make during the call will be forward-looking. Because such statements deal with future events, and are subject to many risks and uncertainties, actual results may differ materially from those in the forward-looking statements. For a full discussion of these risks, and uncertainties, please review our annual report on Form 20-F and our quarterly reports on Form 6-K that are filed with the U.S. Securities and Exchange Commission.

At this time, it is now my pleasure to turn the call over to Phil Serlin, Chief Executive Officer of BioLineRx.

Phil Serlin

Thank you, John, and good morning, everyone. And thank you for joining us on today's call. I'll begin this morning with a recap of the significant licensing agreement that we announced last week with Ayrmid Limited, followed by a review of our third quarter performance, and then Mali Zeevi, our Chief Financial Officer will briefly recap our financials. Afterwards, we will take your questions. Ella Sorani, our Chief Development Officer is also available for Q&A.

Last week, we announced that we executed an exclusive license agreement with Ayrmid Limited, the parent company of Gamida Cell Limited for motixafortide, which is sold in the U.S. under the brand name, APHEXDA. Recall that APHEXDA is our FDA approved and commercially available stem cell mobilization agent indicated in combination with G-CSF for the collection and subsequent autologous transplantation in patients with multiple myeloma.